Login to Your Account



Other News To Note


Thursday, May 19, 2011
Seaside Therapeutics Inc., of Cambridge, Mass., announced the online publication of a review paper in ACS Chemical Neuroscience detailing the evolving scientific and drug development landscape for fragile X syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription